 |
|
|
|
 |
Adjunctive Donepezil Therapy and Genetic Risk Factors of Cognitive Dysfunction in Brain Tumor Survivors
[Protocol 04-122]
- Full Title :
- ADJUNCTIVE DONEPEZIL THERAPY AND GENETIC RISK FACTORS OF COGNITIVE DYSFUNCTION IN BRAIN TUMOR SURVIVORS
- Purpose :
Many brain tumor patients who receive radiation therapy or chemotherapy develop thinking problems ("cognitive dysfunction") as a result of their treatment. The purpose of this study is to find out if treatment with donepezil (Aricept®, a drug commonly used to treat Alzheimer's disease) may improve some aspects of thinking ability in patients with brain tumors who received radiation therapy or chemotherapy. Participants will take several paper-and-pencil tests assessing attention, motor, and memory skills before and after several months of treatment with donepezil, a pill that can be taken at home.
Investigators will also determine if people who have particular genes for a blood-borne substance called "apolipoprotein E" are more likely to have thinking problems after radiation therapy or chemotherapy for brain tumors. The findings of this study will help doctors find out if donepezil can improve cognitive function after cancer treatment, and if some of the cognitive dysfunction that does develop is due in part to having certain genes.
- Eligibility :
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have completed radiation therapy or chemotherapy for a brain tumor within 6 months of entering the study, and be in remission.
- Patients must be able to speak English.
- Patients who are taking antipsychotic or psychostimulant drugs may not participate.
- Patients must be age 18 or older.
For more information and to see if you are eligible for this study, please contact Dr. Denise Correa at 212-639-2082.
|
|
|
|
|
